FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2172206112> ?p ?o ?g. }

• W2172206112 endingPage "290" @default.
• W2172206112 startingPage "282" @default.
• W2172206112 abstract "Lung cancer is the leading cause of cancer related mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for 85% of all cases. Half of the patients at diagnosis of NSCLC are over seventy years old; therefore, the elderly represent a large subgroup of patients affected by advanced NSCLC in our clinical practice. Nevertheless, the elderly are under-represented in clinical trials. Given the fact that old age is frequently associated with several comorbidities, poor general conditions and physiologic reduction in organ function, clinicians must carefully choose the best treatment option for elderly patients with advanced NSCLC, always taking into account the expected risks and benefits. In this paper we perform a review of literature evidence regarding the medical treatment of elderly patients affected by advanced NSCLC, encompassing single-agent chemotherapy, doublet chemotherapy and targeted agents. We conclude that single-agent chemotherapy with a third generation agent (vinorelbine, taxanes, gemcitabine) represents a valid treatment option for elderly patients who are not eligible for a combination chemotherapy due to clinical features such as comorbidities, poor performance status and inadequate organ function. Platinum-based doublet chemotherapy shows similar efficacy in elderly patients as compared to their younger counterpart, despite greater treatment related toxicity and it is indicated in elderly patients with ECOG PS: 0–2, adequate organ function and no major comorbidities. Elderly patients affected by epidermal growth factor receptor (EGFR) mutated NSCLC benefit mostly from a tyrosine kinase inhibitor of EGFR (erlotinib, gefitinib) which is associated with a good toxicity profile. Currently there are no available data to strongly support the use of bevacizumab in combination with first line chemotherapy in the treatment of older adults. Elderly patients affected by NSCLC harboring the EML4-ALK translocation could benefit mostly from a treatment with an oral inhibitor of such a rearrangement (crizotinib)." @default.
• W2172206112 created "2016-06-24" @default.
• W2172206112 creator A5013877464 @default.
• W2172206112 creator A5023215623 @default.
• W2172206112 creator A5046064246 @default.
• W2172206112 creator A5046270433 @default.
• W2172206112 date "2013-07-01" @default.
• W2172206112 modified "2023-09-26" @default.
• W2172206112 title "Medical treatment of advanced non-small cell lung cancer in elderly patients: A review of the role of chemotherapy and targeted agents" @default.
• W2172206112 cites W1593300855 @default.
• W2172206112 cites W1935885922 @default.
• W2172206112 cites W1967394241 @default.
• W2172206112 cites W2005529809 @default.
• W2172206112 cites W2007330294 @default.
• W2172206112 cites W2016004006 @default.
• W2172206112 cites W2026707626 @default.
• W2172206112 cites W2037139573 @default.
• W2172206112 cites W2057458801 @default.
• W2172206112 cites W2070646956 @default.
• W2172206112 cites W2077520669 @default.
• W2172206112 cites W2080037199 @default.
• W2172206112 cites W2086809350 @default.
• W2172206112 cites W2104616343 @default.
• W2172206112 cites W2104830962 @default.
• W2172206112 cites W2111479968 @default.
• W2172206112 cites W2112134197 @default.
• W2172206112 cites W2117700838 @default.
• W2172206112 cites W2121095198 @default.
• W2172206112 cites W2126310082 @default.
• W2172206112 cites W2127405377 @default.
• W2172206112 cites W2127685474 @default.
• W2172206112 cites W2134915662 @default.
• W2172206112 cites W2135797559 @default.
• W2172206112 cites W2137009016 @default.
• W2172206112 cites W2138297714 @default.
• W2172206112 cites W2141032252 @default.
• W2172206112 cites W2143859186 @default.
• W2172206112 cites W2145835533 @default.
• W2172206112 cites W2151522757 @default.
• W2172206112 cites W2158734599 @default.
• W2172206112 cites W2165048128 @default.
• W2172206112 cites W2278430053 @default.
• W2172206112 cites W2515256196 @default.
• W2172206112 cites W2565628176 @default.
• W2172206112 cites W2566863750 @default.
• W2172206112 cites W2601428231 @default.
• W2172206112 doi "https://doi.org/10.1016/j.jgo.2013.04.005" @default.
• W2172206112 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24070465" @default.
• W2172206112 hasPublicationYear "2013" @default.
• W2172206112 type Work @default.
• W2172206112 sameAs 2172206112 @default.
• W2172206112 citedByCount "40" @default.
• W2172206112 countsByYear W21722061122014 @default.
• W2172206112 countsByYear W21722061122015 @default.
• W2172206112 countsByYear W21722061122016 @default.
• W2172206112 countsByYear W21722061122017 @default.
• W2172206112 countsByYear W21722061122018 @default.
• W2172206112 countsByYear W21722061122019 @default.
• W2172206112 countsByYear W21722061122020 @default.
• W2172206112 countsByYear W21722061122021 @default.
• W2172206112 countsByYear W21722061122022 @default.
• W2172206112 crossrefType "journal-article" @default.
• W2172206112 hasAuthorship W2172206112A5013877464 @default.
• W2172206112 hasAuthorship W2172206112A5023215623 @default.
• W2172206112 hasAuthorship W2172206112A5046064246 @default.
• W2172206112 hasAuthorship W2172206112A5046270433 @default.
• W2172206112 hasConcept C121608353 @default.
• W2172206112 hasConcept C126322002 @default.
• W2172206112 hasConcept C143998085 @default.
• W2172206112 hasConcept C177713679 @default.
• W2172206112 hasConcept C2776256026 @default.
• W2172206112 hasConcept C2776694085 @default.
• W2172206112 hasConcept C2776907518 @default.
• W2172206112 hasConcept C2778087573 @default.
• W2172206112 hasConcept C2778239845 @default.
• W2172206112 hasConcept C2779438470 @default.
• W2172206112 hasConcept C2780258809 @default.
• W2172206112 hasConcept C2780350996 @default.
• W2172206112 hasConcept C2780580887 @default.
• W2172206112 hasConcept C535046627 @default.
• W2172206112 hasConcept C71924100 @default.
• W2172206112 hasConceptScore W2172206112C121608353 @default.
• W2172206112 hasConceptScore W2172206112C126322002 @default.
• W2172206112 hasConceptScore W2172206112C143998085 @default.
• W2172206112 hasConceptScore W2172206112C177713679 @default.
• W2172206112 hasConceptScore W2172206112C2776256026 @default.
• W2172206112 hasConceptScore W2172206112C2776694085 @default.
• W2172206112 hasConceptScore W2172206112C2776907518 @default.
• W2172206112 hasConceptScore W2172206112C2778087573 @default.
• W2172206112 hasConceptScore W2172206112C2778239845 @default.
• W2172206112 hasConceptScore W2172206112C2779438470 @default.
• W2172206112 hasConceptScore W2172206112C2780258809 @default.
• W2172206112 hasConceptScore W2172206112C2780350996 @default.
• W2172206112 hasConceptScore W2172206112C2780580887 @default.
• W2172206112 hasConceptScore W2172206112C535046627 @default.
• W2172206112 hasConceptScore W2172206112C71924100 @default.
• W2172206112 hasIssue "3" @default.
• W2172206112 hasLocation W21722061121 @default.

• next